Elucidation of factors enhancing the expression of CD20 and
thereby efficiency of CD20 monoclonal antibodies through
epigenetic drug screening of resistant CLL cells

a 2020

Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Veronika MANČÍKOVÁ, Jiří MAYER, Šárka POSPÍŠILOVÁ et. al.

Základní údaje

Originální název

Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells

Autoři

KOZLOVÁ, Veronika (203 Česká republika, domácí), Aneta LEDEREROVÁ (203 Česká republika, domácí), Veronika MANČÍKOVÁ (703 Slovensko, domácí), Jiří MAYER (203 Česká republika, domácí), Šárka POSPÍŠILOVÁ (203 Česká republika, domácí), Michael DOUBEK (203 Česká republika, domácí) a Michal ŠMÍDA (203 Česká republika, domácí)

Vydání

XVIII. International Workshop on CLL, Edinburgh, Skotsko, 2020

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.280

Kód RIV

RIV/00216224:14740/20:00115243

Organizační jednotka

Středoevropský technologický institut

ISSN

UT WoS

000534385400182

Klíčová slova anglicky

CD20; CLL cells

Štítky

rivok

Příznaky

Mezinárodní význam

Změněno: 16. 3. 2021 19:32, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

In spite of recent advancements in the therapy of B-cell malignancies, CD20-targeted monoclonal antibodies (mAbs) still remain the key part of therapy in clinical practice. Furthermore, the combination of CD20 mAbs with targeted agents is being tested in clinical trials. Therefore, the knowledge of CD20 regulation remains a critical issue to address. Despite using CD20 as the prime target of therapy for decades now, the information about its function and molecular mechanisms remains to be scarce. Since low expression of CD20 on the surface of malignant B cells represents an important basis for CD20 antibody therapy failure, the idea of modulating CD20 levels seems an appealing strategy to enhance the success rate of CD20 immunotherapy

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

MUNI/A/1105/2018, interní kód MU

Název: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VI (Akronym: VýDiTeHeMA VI)

Investor: Masarykova univerzita, Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VI, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

NV15-33561A, projekt VaV

Název: Rezistence na léčbu monoklonálními protilátkami u B-CLL a B-lymfomů: příčiny vzniku a potenciální intervenční strategie

Citovat

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Veronika MANČÍKOVÁ, Jiří MAYER, Šárka POSPÍŠILOVÁ, Michael DOUBEK a Michal ŠMÍDA. Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells. In XVIII. International Workshop on CLL, Edinburgh, Skotsko. 2020. ISSN 1042-8194.

@proceedings{1609558,
   author = {Kozlová, Veronika and Ledererová, Aneta and Mančíková, Veronika and Mayer, Jiří and Pospíšilová, Šárka and Doubek, Michael and Šmída, Michal},
   booktitle = {XVIII. International Workshop on CLL, Edinburgh, Skotsko},
   keywords = {CD20; CLL cells},
   language = {eng},
   title = {Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells},
   url = {https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1732667},
   year = {2020}
}

TY  - CONF
ID  - 1609558
AU  - Kozlová, Veronika - Ledererová, Aneta - Mančíková, Veronika - Mayer, Jiří - Pospíšilová, Šárka - Doubek, Michael - Šmída, Michal
PY  - 2020
TI  - Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells
KW  - CD20
KW  - CLL cells
UR  - https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1732667
N2  - In spite of recent advancements in the therapy of B-cell malignancies, CD20-targeted monoclonal antibodies (mAbs) still remain the key part of therapy in clinical practice. Furthermore, the combination of CD20 mAbs with targeted agents is being tested in clinical trials. Therefore, the knowledge of CD20 regulation remains a critical issue to address. Despite using CD20 as the prime target of therapy for decades now, the information about its function and molecular mechanisms remains to be scarce. Since low expression of CD20 on the surface of malignant B cells represents an important basis for CD20 antibody therapy failure, the idea of modulating CD20 levels seems an appealing strategy to enhance the success rate of CD20 immunotherapy
ER  -

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Veronika MANČÍKOVÁ, Jiří MAYER, Šárka POSPÍŠILOVÁ, Michael DOUBEK a Michal ŠMÍDA. Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells. In \textit{XVIII. International Workshop on CLL, Edinburgh, Skotsko}. 2020. ISSN~1042-8194.

Přehled o publikaci